Evidence map›Paper›PMID 34763046›Full record

ArticleJournal of ethnopharmacology2022

In vitro antibacterial activity of nimbolide against Helicobacter pylori.

Marina R Wylie, Ian H Windham, Faith C Blum, Hannah Wu, D Scott Merrell

Open access · greenAbstract read
In one paragraph

Article in Journal of ethnopharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 26 citations in OpenAlex.

  1. A comprehensive review ofBiochemistry and biophysics reports · 2026
    Review
  2. Article
  3. Article
  4. Exploring the Antibacterial Activity ofTropical life sciences research · 2024
    Article
  5. Unveiling the Neem (Plants (Basel, Switzerland) · 2024
    Article
  6. Article
  7. Biofilm ofAntibiotics (Basel, Switzerland) · 2023
    Review
  8. Review
  9. Review
  10. Research on antibiotic resistance inFrontiers in microbiology · 2023
    Article
  11. Frontiers in microbiology · 2023
    Review
  12. Article
  13. The Antimicrobial Potential of the Neem TreeFrontiers in pharmacology · 2022
    Review
  14. Review
  15. Infection and drug resistance · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Marina R WylieDepartment of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, MD, 20814, United States.
Ian H WindhamDepartment of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, MD, 20814, United States.
Faith C BlumDepartment of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, MD, 20814, United States.
Hannah WuDepartment of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, MD, 20814, United States.
D Scott MerrellDepartment of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, MD, 20814, United States. Electronic address: douglas.merrell@usuhs.edu.
Uniformed Services University of the Health Sciences · US

Funding

Contribution of Helicobacter pylori HomA and HomB to colonization and diseaseR21AI156357 · NIAID · HENRY M. JACKSON FDN FOR THE ADV MIL/MED · PI MELTON-CELSA, ANGELA · 2021 to 2022
$419k
NIAID NIH HHS R21 AI156357
6 · The paper itself

Abstract

ethnopharmacological relevanceNimbolide is one of hundreds of phytochemicals that have been identified within the neem tree (Azadirachta indica A. Juss). As an evergreen tree native to the Indian subcontinent, components of the neem tree have been used for millennia in traditional medicine to treat dental, gastrointestinal, urinary tract, and blood-related ailments, ulcers, headaches, heartburn, and diabetes. In modern times, natural oils and extracts from the neem tree have been found to have activities against a variety of microorganisms, including human pathogens. AIM OF THE STUDY: Helicobacter pylori, a prevalent gastric pathogen, shows increasing levels of antibiotic resistance. Thus, there is an increasing demand for novel therapeutics to treat chronic infections. The in vitro activity of neem oil extract against H. pylori was previously characterized and found to be bactericidal. Given the numerous phytochemicals found in neem oil extract, the present study was designed to define and characterize specific compounds showing bactericidal activity against H. pylori. MATERIALS AND

methodsAzadirachtin, gedunin, and nimbolide, which are all common in neem extracts, were tested for antimicrobial activity; the minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) were determined for nine strains of H. pylori. The specific properties of nimbolide were further characterized against H. pylori strain G27. Bactericidal kinetics, reversibility, effectiveness at low pH, and activity under bacteriostatic conditions were examined. The hemolytic activity of nimbolide was also measured. Finally, neem oil extract and nimbolide effectiveness against H. pylori biofilms were examined in comparison to common antibiotics used to treat H. pylori infection.

resultsNimbolide, but not azadirachtin or gedunin, was effective against H. pylori; MICs and MBCs against the nine tested strains ranged between 1.25-5 μg/mL and 2.5-10 μg/mL, respectively. Additionally, neem oil extract and nimbolide were both effective against H. pylori biofilms. Nimbolide exhibited no significant hemolytic activity at biologically relevant concentrations. The bactericidal activity of nimbolide was time- and dose-dependent, independent of active H. pylori growth, and synergistic with low pH. Furthermore, nimbolide-mediated H. pylori cell death was irreversible after exposure to high nimbolide concentrations (80 μg/mL, after 2 h of exposure time and 40 μg/mL after 8 h of exposure).

conclusionsNimbolide has significant bactericidal activity against H. pylori, killing both free living bacterial cells as well as cells within a biofilm. Furthermore, the lack of hemolytic activity, synergistic activity at low pH and bactericidal properties even against bacteria in a state of growth arrest are all ideal pharmacological and biologically relevant properties for a potential new agent. This study underscores the potential of neem oil extract or nimbolide to be used as a future treatment for H. pylori infection.

Indexed as

Anti-Bacterial AgentsAzadirachtaDrug DiscoveryGlyceridesHelicobacter InfectionsHelicobacter pyloriHumansLimoninsMedicine, TraditionalMicrobial Sensitivity TestsPhytochemicalsPlant ExtractsPlant LeavesTerpenesAnti-Bacterial AgentsGlyceridesLimoninsneem oilnimbolidePhytochemicalsPlant ExtractsTerpenesAntibacterial activityAzadirachta indicaBiofilmsHelicobacter pyloriNeem oil extractNimbolide

Identifiers

PMID34763046
PMCPMC8714693
OpenAlexW3212209893

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.